论文部分内容阅读
目的观察丽珠肠乐及莫沙必利治疗慢加急性(亚急性)肝衰竭临床疗效。方法将2003年1月至2007年12月间住院的慢加急性(亚急性)肝衰竭患者随机分为治疗组和对照组,对照组仅给予内科综合治疗,治疗组在此基础上加用丽珠肠乐及莫沙必利口服治疗,疗程1月。结果治疗组有效率(79%)优于对照组(43%),治疗组治疗后出血、感染、肝性脑病、肝肾综合征、腹水并发症少于对照组。结论丽珠肠乐及莫沙必利治疗慢加急性(亚急性)肝衰竭临床疗效显著,预后改善明显。
Objective To observe the clinical efficacy of Lizhu Changle and mosapride in the treatment of acute and acute acute pancreatitis (subacute). Methods Patients with slow-onset acute (subacute) liver failure who were hospitalized from January 2003 to December 2007 were randomly divided into treatment group and control group. The control group received only comprehensive medical treatment. In addition, Cholesterol and mosapride oral treatment, treatment in January. Results The effective rate (79%) in the treatment group was better than that in the control group (43%). The bleeding, infection, hepatic encephalopathy, hepatorenal syndrome and ascites complications in the treatment group were less than those in the control group. Conclusions The results showed that Lactucae and Mosapride had a significant therapeutic effect on slow and acute (subacute) liver failure and their prognosis improved significantly.